This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
We have read with interest the article by Dr. Robert P. Burns, "A Double Blind Study of IDU in Human Herpes Simplex Keratitis" (Arch Ophthal 70:381-384, 1963).The results of Dr. Burns' trial and his comment that "IDU warrants further study but not universal approval at this time as a therapy for herpetic keratitis" are in close agreement with our own conclusions following a controlled trial of the drug in human herpetic keratitis conducted at the Oxford Eye Hospital, Oxford, England, between May and December, 1962, and published as a letter to the Editor of Lancet (1:830-831, 1963), and a paper to the British Journal of Ophthalmology (47:449-456, 1963).Dr. Burns has rightly pointed out that herpes simplex keratitis is a self-limited eye disease and stressed "the necessity of considering the placebo effect in therapy of self-limited eye infections." He also questions the diagnosis of herpetic keratitis
Luntz MH. IDOXURIDINE (IDU) IN ENGLAND. Arch Ophthalmol. 1964;72(1):148. doi:10.1001/archopht.1964.00970020148030
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.